NYSE$ZBH

Zimmer Biomet Holdings Inc · Q4 2021 earnings

Q4 2021 earnings · · Investor relations

Briefing

Zimmer Biomet's financial performance in Q4 2021 was impacted by the COVID-19 pandemic and China's volume-based procurement.

Zimmer Biomet reported a decrease in net sales for the fourth quarter of 2021, alongside a net loss, although adjusted earnings per share showed a positive figure. The company's performance was impacted by the ongoing COVID-19 pandemic and China's volume-based procurement.

  • Fourth quarter net sales decreased by 2.3% to $2.038 billion, a 0.8% decrease on a constant currency basis.
  • Diluted loss per share for the fourth quarter was $0.40, while adjusted diluted earnings per share were $1.95.
  • Net loss for the fourth quarter was $84.0 million, but adjusted net earnings were $409.2 million.
  • The company provided full-year 2022 financial guidance for RemainCo Zimmer Biomet.

Headline financials

Total Revenue

$2.04B

Previous: $2.09B-2.3%
EPS (adj)

$1.95

Previous: $2.11-7.6%
Capital Expenditures

$63.1M

Previous: $27.7M+127.8%
Free Cash Flow

$303M

Previous: $329M-7.9%
Net Income

-$84M

Previous: $334M-125.2%
Operating Income

$79.1M

Previous: $241M-67.1%
Gross Profit

$1.24B

Previous: $1.44B-13.7%
Cash & Equivalents

$479M

Previous: $802M-40.3%
Total Assets

$23.5B

Previous: $24.4B-3.9%
Stock-Based Comp

$17.7M

Previous: $17.7M+0.0%

Revenue & EPS history

Zimmer Biomet · Revenue · Quarterly

$2.04B

Q4 2021-2.3%vs Q4 2020
Beat estimate in 13 of 16 quarters(81%)
ActualEstimate

Revenue by segment

Zimmer Biomet · $1.61B total across 3 segments · Q4 2021

  • Knees Net Sales
    $720M-2.3%
  • Hips Net Sales
    $481M-4.6%
  • S.E.T. Net Sales
    $411M+9.2%

Forward guidance

The Company is providing the following full-year 2022 financial guidance for RemainCo Zimmer Biomet – this guidance does not include any projected financial results from the businesses that are part of the planned spinoff of ZimVie from the Company.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q4 2021

Historical avgQ4 2021

-0.4%

Avg return

Earnings day

-1.7%

Avg return

5 days after

-2.3%

Avg return

30 days after

42%

30 / 72 earnings

Positive

+11.9%

Q3 2020

Best reaction

-15.3%

Q3 2016

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-1.1%-10.5%-11.5%
Q4 2025+1.9%+7.5%+3.2%
Q3 2025-15.2%-14.0%-8.6%
Q1 2025-11.6%-7.0%-10.7%
Q4 2024-5.1%-8.6%-0.2%
Q3 2024+2.9%+4.4%+7.9%
Q2 2024-0.8%-2.3%-4.3%
Q1 2024+1.8%+1.6%-3.7%
Q4 2023-3.7%-3.4%-0.6%
Q3 2023-4.1%-3.5%+7.3%
Q2 2023-7.1%-8.6%-13.8%
Q1 2023+0.6%-0.7%-8.3%
Q4 2022+0.9%+2.6%-0.9%
Q3 2022-5.7%-3.9%+10.0%
Q2 2022+5.3%+3.2%-2.7%
Q1 2022+4.7%-0.3%+1.2%
Q4 2021-2.4%-5.4%-1.4%
Q3 2021-4.8%-9.7%-18.5%
Q2 2021-9.1%-8.6%-8.5%
Q1 2021-2.5%-3.1%-10.1%
Q4 2020-0.6%-0.2%-1.4%
Q3 2020+11.9%+7.2%+7.0%
Q2 2020-1.5%+2.7%+3.5%
Q1 2020-6.8%-7.8%+10.2%
Q4 2019+6.2%+5.3%-13.0%
Q3 2019+4.9%+5.5%+8.1%
Q2 2019+8.6%+9.1%+7.9%
Q1 2019-3.1%-2.8%-8.2%
Q4 2018+7.8%+7.9%+14.5%
Q3 2018-5.6%-7.0%-7.7%
Q2 2018+8.0%+7.1%+7.1%
Q1 2018+5.7%+5.8%+0.4%
Q4 2017-0.2%-1.3%-10.9%
Q3 2017-7.7%-10.1%-5.8%
Q2 2017-3.8%-6.5%-12.1%
Q1 2017-4.5%-3.7%-4.9%
Q4 2016+2.7%+2.4%+2.3%
Q3 2016-15.3%-15.9%-16.9%
Q2 2016+6.9%+6.4%+5.6%
Q1 2016-0.1%
Q4 2015-2.3%
Q3 2015+6.8%
Q2 2015-2.7%
Q1 2015-4.3%
Q4 2014-2.1%
Q3 2014+5.1%
Q2 2014-2.3%
Q1 2014+9.9%
Q4 2013+0.8%
Q3 2013-3.3%
Q2 2013+0.5%
Q1 2013+0.6%
Q4 2012-1.3%
Q3 2012+2.0%
Q2 2012-3.5%
Q1 2012-0.6%
Q4 2011-1.3%
Q3 2011+3.7%
Q2 2011-5.6%
Q1 2011+0.5%
Q4 2010+2.2%
Q3 2010+3.6%
Q2 2010-1.5%
Q1 2009-0.8%
Q1 2010+1.6%
Q4 2009-0.2%
Q3 2009+4.0%
Q3 2008+4.0%
Q4 2007-1.0%
Q2 2008-1.0%
Q2 2009-1.0%
Q4 2008-1.0%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro